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Abstract
Background & Aims:	Although	hepatitis	B	virus	(HBV)	and	hepatitis	C	virus	(HCV)	in-
fections	remain	major	risk	factors	for	hepatocellular	carcinoma	(HCC),	non-	viral	causes	
of	HCC,	particularly	non-	alcoholic	fatty	liver	disease	(NAFLD),	are	becoming	increas-
ingly	prevalent.	The	aim	of	this	study	was	to	compare	the	clinical	characteristics	and	
survival	of	cryptogenic	and	viral	HCC.
Methods:	We	 conducted	 a	 retrospective	 cohort	 study	 involving	 3878	 consecutive	
HCC	patients	seen	at	two	tertiary	centres	in	the	United	States	and	one	in	Taiwan	from	
2004	 to	 2014.	We	 compared	 the	 clinical	 characteristics,	 treatment	 and	 survival	 of	
patients	 by	 underlying	 aetiology:	 cryptogenic	 (n	=	696),	 HBV	 (n	=	1304)	 or	 HCV	
(n	=	1878).
Results:	Cirrhosis	was	present	in	66.8%	of	the	cryptogenic	HCC	patients,	compared	
with	 74.7%	 of	 HBV-	related	 HCC	 (HBV-	HCC)	 (P = .001)	 and	 85.9%	 of	 HCV-	HCC	
(P < .001).	Compared	to	viral	HCC,	cryptogenic	HCC	patients	presented	with	 larger	
tumours	and	at	 later	stages	of	disease.	Five-	year	overall	survival	was	16.3%	among	
cryptogenic	HCC	patients	compared	with	31.9%	among	HBV-	HCC	patients	and	27.7%	
among	HCV-	HCC	patients	(P < .001	for	both	by	the	log-	rank	test).	HCC	aetiology	was	
not	an	 independent	predictor	of	survival,	though	ethnicity,	cirrhosis	status,	meeting	
Milan	criteria	and	treatment	allocation	were.
Conclusions:	 Compared	with	 viral	 HCC	 patients,	 those	with	 cryptogenic	 HCC	 had	
lower	prevalence	of	cirrhosis,	were	diagnosed	with	larger	tumours	at	more	advanced	
stages	of	disease,	and	had	poorer	overall	 survival.	Additional	efforts	are	needed	 to	
identify	patients	at	risk	of	cryptogenic	HCC	and	to	identify	cryptogenic	HCC	at	earlier	
stages	of	disease.
K E Y W O R D S
cryptogenic	HCC,	hepatitis	B,	hepatitis	C,	hepatocellular	carcinoma
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1  | INTRODUCTION
Hepatocellular	carcinoma	(HCC)	is	a	major	cause	of	cancer	mortality	
worldwide	and	was	the	fourth	 leading	cause	of	death	with	800	000	
deaths	in	2015.1	In	the	United	States	and	Taiwan,	where	we	practice,	
5-	year	survival	for	liver	cancer	is	18%	and	28.9%	respectively.2,3
While	chronic	infections	with	hepatitis	B	virus	(HBV)	and	hepatitis	
C	virus	(HCV)	are	the	major	HCC	risk	factors	globally	(53%	and	25%,	
respectively),	 other	 chronic	 liver	 diseases	 are	 also	 associated	 with	
HCC,	such	as	non-	alcoholic	fatty	liver	disease	(NAFLD).4	NAFLD	is	an	
increasingly	important	cause	of	HCC	with	an	estimated	global	preva-
lence	of	25%	and	rising.5-8
Current	HCC	surveillance	guidelines	focus	on	HCC	in	the	setting	
of	chronic	viral	hepatitis	or	cirrhosis.9	However,	a	growing	body	of	ev-
idence	suggests	that	a	third	or	more	of	NAFLD-	related	HCC	develops	
in	 patients	without	 a	 known	 history	 of	 cirrhosis.10-15	 Some	 studies	
have	also	 found	 that	patients	with	non-	viral	 aetiologies	of	HCC	are	
diagnosed	at	more	advanced	stages,	possibly	because	of	lower	rates	of	
surveillance.14-16	More	data	are	needed	to	understand	the	epidemiol-
ogy	of	HCC	associated	with	non-	viral	aetiologies,	particularly	NAFLD,	
in	order	to	inform	guidelines	moving	forward.
A	clear-	cut	diagnosis	of	NAFLD	or	 its	 inflammatory	counterpart,	
non-	alcoholic	 steatohepatitis	 (NASH),	 is	 not	 always	 possible	 at	 the	
time	of	HCC	diagnosis.	Over	time,	hepatic	steatosis	may	be	replaced	
by	fibrosis	and	cirrhosis,	and	the	metabolic	derangements	associated	
with	NAFLD,	such	as	obesity,	may	not	be	apparent	in	end-	stage	liver	
disease.17	As	such,	there	is	increasing	acknowledgement	that	a	signif-
icant	proportion	of	cryptogenic	HCC—that	is,	HCC	in	the	absence	of	
chronic	viral	infection,	alcohol	use	or	other	diagnosed	liver	disease—is	
likely	because	of	NAFLD.5,18-20
To	augment	the	body	of	knowledge	on	cryptogenic	HCC,	we	con-
ducted	a	retrospective	cohort	study	of	3878	consecutive	HCC	patients	
diagnosed	between	2004	and	2014	in	the	United	States	and	Taiwan	
comparing	the	clinical	characteristics	and	survival	of	viral-	related	HCC	
against	those	of	cryptogenic	HCC.
2  | PATIENTS AND METHODS
2.1 | Study design and patient population
This	retrospective	cohort	study	 involved	3878	consecutive	cases	of	
HBV-	related,	HCV-	related	or	 cryptogenic	HCC	seen	at	 two	 tertiary	
hospitals	in	the	United	States	and	one	in	Taiwan	between	2004	and	
2014.	HCC	diagnosis	was	based	on	histology,	cytology,	or	non-	invasive	
criteria	recommended	by	the	American	Association	for	the	Study	of	
Liver	Diseases	(AASLD).9	The	study	protocol	was	approved	by	the	in-
stitutional	review	boards	of	the	Stanford	University	Medical	Center,	
the	 Mayo	 Clinic	 in	 Rochester,	 and	 Kaohsiung	 Medical	 University	
Hospital.	An	exemption	from	informed	consent	was	granted	because	
of	the	minimal	risk	posed	to	participants	in	this	chart	review	study.
Adults	 aged	 18	 or	 older	 were	 eligible	 for	 inclusion	 if	 they	 had	
HCC	and	an	underlying	diagnosis	of	HBV,	HCV,	or	 if	 their	HCC	was	
cryptogenic.	Diagnoses	of	HBV	and	HCV	were	based	on	serological	
testing	as	well	as	nucleic	acid	tests	for	viraemia.	Cryptogenic	HCC	was	
defined	as	HCC	in	the	absence	of	any	history	of	regular	alcohol	use	
and	without	a	confirmed	chronic	 liver	disease	such	as	chronic	hepa-
titis	B	or	C,	 autoimmune	or	metabolic	 liver	disease	 such	as	primary	
biliary	cirrhosis,	primary	sclerosing	cholangitis,	haemochromatosis	or	
Wilson’s	disease.	Patients	with	HCC	in	the	presence	of	multiple	un-
derlying	liver	diseases	(eg,	HBV	and	HCV	co-	infection)	were	excluded.	
Alcohol	intake	was	not	routinely	quantified,	but	cases	of	HCC	deemed	
to	be	alcohol-	related	by	the	examining	physicians	(as	documented	in	
their	clinical	notes)	were	excluded.	Patient	inclusion	and	exclusion	are	
illustrated	in	Figure	S1.
2.2 | Definition of cirrhosis
Cirrhosis	status	was	determined	based	on	histology,	imaging	and	chart	
review.	Patients	were	considered	to	have	cirrhosis	if	they	had	F4	fi-
brosis	on	histology,	if	they	had	clinical	evidence	of	portal	hypertension	
(platelets	 <120	000/μL,	 splenomegaly,	 ascites	 or	 gastroesophageal	
varices	on	 imaging)	or	 if	 they	had	hepatic	decompensation	 (hepatic	
encephalopathy,	 ascites,	 variceal	 bleeding)	within	6	months	of	HCC	
diagnosis.
2.3 | Tumour staging and survival outcomes
Tumour	stage	was	assessed	by	the	Milan	criteria	 for	 transplant	and	
the	Barcelona	clinic	liver	cancer	(BCLC)	staging	system.	Tumour	size	
and	 other	 imaging	 characteristics	were	 derived	 from	 computed	 to-
mography	(CT)	or	magnetic	resonance	imaging	(MRI).
Survival	data	were	based	on	 the	date	of	HCC	diagnosis	and	 the	
date	of	death	or	last	follow-	up	date.
2.4 | Statistical analysis
Descriptive	 statistics	 of	 categorical	 variables	were	 reported	 as	 pro-
portions	(%),	while	continuous	variables	were	reported	as	means	with	
standard	deviations	or	medians	with	interquartile	ranges.	Comparisons	
Key points
•	 One-third	of	cryptogenic	hepatocellular	carcinoma	(HCC)	
patients	were	non-cirrhotic,	significantly	more	than	viral	
HCC	patients.
•	 Cryptogenic	HCC	patients	presented	with	larger	tumours	
and	at	more	advanced	stages	of	disease	than	viral	HCC	
patients.
•	 Compared	to	viral	HCC	patients,	those	with	cryptogenic	
HCC	had	worse	overall	 survival	 despite	often	 receiving	
treatments	with	curative	intent.
•	 Cryptogenic	 aetiology	 of	HCC	was	 not	 an	 independent	
predictor	 of	 survival	 after	 adjusting	 for	 factors	 such	 as	
stage	of	disease	and	treatment	strategy.
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of	descriptive	statistics	were	made	using	the	Student’s	t	test,	the	chi-	
square	test,	or	the	Mann-	Whitney	U	test	for	normally	distributed	con-
tinuous	variables,	categorical	variables,	and	non-	normally	distributed	
continuous	variables	respectively.
Five-	year	overall	survival	was	the	primary	outcome.	The	primary	
predictor	 variable	 was	 HCC	 aetiology	 (HBV,	 HCV	 or	 cryptogenic).	
Secondary	predictors	 included	ethnicity,	cirrhosis,	 tumour	stage	and	
treatment	 strategy.	 Treatments	 such	 as	 liver	 transplantation,	 sur-
gical	 resection	 and	 radiofrequency	 ablation	 (RFA)	 were	 considered	
treatments	with	curative	 intent,	while	treatments	such	as	transcath-
eter	 arterial	 chemoembolization	 (TACE),	 radioembolization	 (RE)	 and	
sorafenib	were	considered	palliative.	Univariate	and	multivariate	sur-
vival	models	were	constructed	using	Cox	proportional	hazards	models.	
Relevant	variables	 that	were	 significant	 (defined	as	 association	with	
P < .05)	 in	 the	 univariate	 analysis	were	 included	 in	 the	multivariate	
model.	Kaplan-	Meier	survival	curves	and	5-	year	survival	rates	for	in-
dependent	subgroups	were	compared	using	the	log-	rank	test.
All	statistical	analyses	were	performed	in	Stata,	version	14	(Stata	
Corporation,	College	Station,	TX,	USA).	Statistical	significance	was	de-
fined	as	a	two-	tailed	P	value	of		<	.05.
3  | RESULTS
3.1 | Baseline patient clinical characteristics
Of	 the	 3878	 HCC	 patients,	 696	 (18.0%)	 were	 cryptogenic,	 1304	
(33.6%)	were	HBV-	related	and	1878	(48.4%)	were	HCV-	related.	The	
median	date	of	HCC	diagnosis	was	2008.5	for	cryptogenic	HCC	pa-
tients,	2008	for	HBV-	related	HCC	(HBV-	HCC)	patients,	and	2009	for	
HCV-	HCC	patients.	Baseline	clinical	and	laboratory	characteristics	of	
the	patients	by	HCC	aetiology	are	shown	in	Tables	1	and	2.	Compared	
to	 patients	 with	 HBV-	HCC	 or	 HCV-	HCC,	 those	 with	 cryptogenic	
HCC	were	older,	had	higher	body	mass	index	(BMI)s,	and	were	more	
likely	to	have	metabolic	comorbidities	such	as	obesity,	diabetes	and	
hypertension.
Clinically	apparent	cirrhosis	was	less	common	among	cryptogenic	
HCC	patients;	66.8%	of	cryptogenic	patients	had	cirrhosis	compared	
to	74.7%	of	HBV-	HCC	patients	(P = .001)	and	85.9%	of	HCV-	HCC	pa-
tients	(P < .001).
3.2 | Tumour characteristics
Table	3	compares	tumour	characteristics	across	the	three	aetiologies.	
Patients	with	cryptogenic	HCC	had	larger	tumours	and	more	advanced	
disease	 at	 presentation	 than	patients	with	HBV-	HCC	or	HCV-	HCC.	
The	median	maximum	tumour	size	of	cryptogenic	HCC	patients	was	
6.0	cm	at	diagnosis	compared	to	3.9	cm	for	HBV-	HCC	and	3.2	cm	for	
HCV-	HCC	(P < .001	for	both	comparisons).	Cryptogenic	HCC	patients	
were	more	likely	to	have	extrahepatic	metastases	(16.2%)	compared	to	
HBV-	HCC	(11.2%,	P = .002)	and	HCV-	HCC	(6.7%,	P < .001).	Less	than	
one-	third	(28.2%)	of	cryptogenic	HCC	patients	met	Milan	criteria	for	
transplantation	compared	to	nearly	half	of	HBV-	HCC	patients	(45.4%)	
and	55.8%	of	HCV-	HCC	patients	(P < .001	for	both	comparisons).
3.3 | Treatment allocation
Despite	 having	 more	 advanced	 tumours	 at	 presentation,	 cryp-
togenic	 HCC	 patients	 were	 significantly	 more	 likely	 to	 receive	
TABLE  1 Baseline	patient	clinical	characteristics,	by	hepatocellular	carcinoma	(HCC)	aetiology
Cryptogenic (N = 696) HBV (N = 1304) P value HCV (N = 1878) P value
Overall 
(N = 3878)
Agea	(y) 67.2	±	13.4 58.3	±	12.2 <.001 63.0	±	9.9 <.001 62.2	±	11.8
Male 440	(63.2%) 1074	(82.4%) <.001 1248	(66.5%) .125 2762	(71.2%)
Asian 317	(45.6%) 1251	(95.9%) <.001 1040	(55.4%) <.001 2608	(67.3%)
US	site 412	(59.2%) 349	(26.8%) <.001 1054	(56.1%) .162 1815	(46.8%)
History	of	regular	alcohol	use 0	(0%) 380	(29.3%) <.001 801	(43.0%) <.001 1181	(30.7%)
Body	mass	indexa	(kg/m2) 27.7	±	6.2 24.4	±	4.0 <.001 26.0	±	5.3 <.001 25.8	±	5.2
Hypertension	(HTN) 354	(58.2%) 403	(31.7%) <.001 855	(47.1%) <.001 1612	(43.6%)
Diabetes	(DM) 278	(45.7%) 299	(23.5%) <.001 594	(32.8%) <.001 1171	(31.8%)
≥2	of	obesityb,	HTN,	DM 297	(44.8%) 295	(22.9%) <.001 604	(32.5%) <.001 1196	(31.4%)
Coronary	artery	disease 130	(21.5%) 40	(3.1%) <.001 108	(6.0%) <.001 278	(7.6%)
Symptomatic	at	diagnosis 395	(58.0%) 491	(39.1%) <.001 670	(42.8%) <.001 1556	(44.4%)
Cirrhosis 338	(66.8%) 919	(74.7%) .001 1497	(85.9%) <.001 2754	(79.2%)
Ascites 198	(30.8%) 345	(27.2%) .099 442	(24.3%) .001 985	(26.4%)
Encephalopathy 56	(8.4%) 79	(6.2%) .063 152	(8.3%) .92 287	(7.6%)
CAD,	coronary	artery	disease;	HBV,	hepatitis	B	virus;	HCV,	hepatitis	C	virus.
P	values	are	for	the	comparison	to	cryptogenic.
aReported	as	mean	±	standard	deviation.
bObesity	defined	as	BMI	≥	30	for	non-	Asians	and	≥25	for	Asians	(both	East	Asian	and	South	Asian).
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treatments	 with	 curative	 intent	 compared	 to	 patients	 with	 viral	
aetiologies	 (31.5%	 for	 cryptogenic	 HCC,	 23.0%	 for	 HBV-	HCC;	
P < .001,	 and	 26.0%	 for	 HCV-	HCC;	 P = .011)	 (Table	4).	 Resection	
in	particular	was	more	 common	among	cryptogenic	HCC	patients	
(26.6%)	than	in	HBV-	HCC	(16.5%,	P < .001)	or	HCV-	HCC	patients	
(11.2%,	P < .001).
3.4 | Overall survival
Average	length	of	follow-	up	was	1.63	years	(SD:	1.97	years).	The	av-
erage	length	of	follow-	up	by	aetiology	was	1.1	years	(SD:	1.51	years)	
for	 the	 cryptogenic	 group,	 1.6	years	 (SD:	 2.07	years)	 for	 the	 HBV	
group	and	1.8	years	(SD:	2.00	years)	for	the	HCV	group.	The	rate	of	
loss	 to	 follow-	up	at	5	years	was	not	 significantly	different	between	
the	cryptogenic	HCC	group	and	either	of	the	viral	HCC	groups	(47.0%	
cryptogenic,	51.7%	HBV,	46.8%	HCV;	crypto	vs	HBV	P = .06,	crypto	
vs	HCV	P = .92).
Five-	year	overall	survival	was	worse	among	cryptogenic	HCC	patients	
(16.3%)	compared	with	either	HBV-	HCC	(31.9%,	P	<	.001)	or	HCV-	HCC	
patients	(27.7%,	P	<	.001)	(Figure	1A).	This	result	persisted	after	stratifi-
cation	by	cirrhosis	(Figure	1B,C).	Cirrhotic	cryptogenic	HCC	patients	had	
worse	5-	year	survival	than	cirrhotic	viral	HCC	(19.4%	vs	26.5%,	P	<	.001).	
Similarly,	non-	cirrhotic	cryptogenic	HCC	patients	had	worse	5-	year	sur-
vival	than	non-	cirrhotic	viral	HCC	(28.2%	vs	47.7%,	P	<	.001).
Since	cryptogenic	HCC	patients	underwent	curative	treatments	at	
a	higher	rate	than	viral	HCC	patients,	we	also	examined	survival	by	ae-
tiology	for	patients	receiving	either	surgical	resection	or	RFA	as	their	
primary	HCC	therapy.	Cryptogenic	HCC	patients	undergoing	either	re-
section	or	RFA	still	had	worse	5-	year	overall	survival	(38.1%)	than	either	
HBV-	HCC	(67.3%,	P < .001)	or	HCV-	HCC	(45.2%,	P = .02)	(Figure	1D).
TABLE  2 Baseline	patient	laboratory	characteristics,	by	hepatocellular	carcinoma	(HCC)	aetiology
Cryptogenic (N = 696) HBV (N = 1304) P value HCV (N = 1878) P value Overall (N = 3878)
Platelet countb	(K/μL) 183.5	(IQR	121-	259) 152	(IQR	104-	217) <.001 114	(IQR	76-	163) <.001 137	(IQR	89-	197)
Total	bilirubinb	(mg/dL) 0.9	(IQR	0.6-	1.5) 1	(IQR	0.7-	1.5) .003 1.1	(IQR	0.7-	1.7) <.001 1	(IQR	0.7-	1.6)
Albumina	(g/dL) 3.5	±	0.6 3.5	±	0.6 .323 3.3	±	0.6 <.001 3.4	±	0.6
International	normalized	
ratiob
1.1	(IQR	1-	1.2) 1.1	(IQR	1-	1.2) <.001 1.1	(IQR	1-	1.3) <.001 1.1	(IQR	1-	1.2)
Aspartate	transaminaseb 
(U/L)
55	(IQR	36-	95) 59	(IQR	38-	108) .068 80.5	(IQR	52-	124) <.001 69	(IQR	43-	115)
Alanine transaminaseb 
(U/L)
42	(IQR	27-	61) 48	(IQR	34-	75) <.001 67	(IQR	40-	107) <.001 69	(IQR	43-	115)
Log10 AFP
b	(ng/dL) 3.3	(IQR	1.6-	7.2) 4.3	(IQR	2.3-	6.9) <.001 3.7	(IQR	2.3-	6) .008 3.8	(IQR	2.2-	6.4)
CTP	Ac 124	(47.7%) 508	(62.9%) <.001 719	(56.0%) .027 1351	(57.5%)
CTP	B 113	(43.5%) 247	(30.6%) 488	(38.1%) 848	(36.1%)
CTP	C 23	(8.9%) 53	(6.6%) 76	(5.9%) 152	(6.5%)
MELDb 9	(IQR	7-	12) 9	(IQR	7-	11) .787 9	(IQR	8-	13) .001 9	(IQR	7-	12)
AFP,	alpha-	foetoprotein;	HBV,	hepatitis	B	virus;	HCV,	hepatitis	C	virus;	MELD,	model	for	end-	stage	liver	disease.
P	values	are	for	the	comparison	to	cryptogenic.
aReported	as	mean	±	standard	deviation.
bReported	as	median	with	interquartile	range.
cChild-	Turcotte	Pugh	class	calculated	for	cirrhotic	patients	only.
TABLE  3 Tumour	characteristics,	by	hepatocellular	carcinoma	(HCC)	aetiology
Cryptogenic 
(N = 696) HBV (N = 1304) P value HCV (N = 1878) P value Overall (N = 3878)
Max.	tumour	size	(cm) 6.0	(IQR	3.4-	9.7) 3.9	(IQR	2.4-	7.3) <.001 3.2	(IQR	2.1-	5.2) <.001 3.7	(IQR	2.3-	6.5)
Multifocal 276	(44.5%) 342	(33.5%) <.001 602	(35.0%) <.001 1220	(36.3%)
Vascular	invasion 127	(19.7%) 203	(17.9%) .347 232	(13.0%) <.001 562	(15.8%)
Extrahepatic	
metastasis
107	(16.2%) 140	(11.2%) .002 123	(6.7%) <.001 370	(9.9%)
Within	Milan	criteria 187	(28.2%) 530	(45.4%) <.001 974	(55.8%) <.001 1691	(47.3%)
BCLC	C/D 214	(46.8%) 323	(35.5%) <.001 363	(26.4%) <.001 900	(32.8%)
BCLC,	Barcelona	clinic	liver	cancer;	HBV,	hepatitis	B	virus;	HCV,	hepatitis	C	virus.
P	values	are	for	the	comparison	to	cryptogenic.
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3.5 | Predictors of survival
Favourable	predictors	of	5-	year	survival	in	univariate	Cox	propor-
tional	 hazard	models	 included	 female	 gender,	 younger	 age,	Asian	
or	Hispanic	 ethnicity	 (compared	 to	 Caucasian	 ethnicity),	 absence	
of	 cirrhosis,	 absence	 of	 coronary	 artery	 disease	 (CAD),	 meeting	
Milan	 criteria,	 curative	 or	 palliative	 treatments	 (compared	 to	 no	
treatment)	and	viral	aetiology	 (Table	5).	 In	 the	multivariate	analy-
sis,	 viral	 aetiology	 was	 no	 longer	 a	 significant	 predictor	 of	 sur-
vival.	Significant	independent	predictors	of	survival	were	Asian	or	
Hispanic	ethnicity,	absence	of	cirrhosis,	lower	model	for	end-	stage	
liver	disease	 (MELD)	score,	meeting	Milan	criteria	and	curative	or	
palliative	treatments.
3.6 | Analysis by United States vs Taiwan sites
The	 distribution	 of	 aetiologies	 and	 treatment	 strategies	 differed	
between	the	US	and	Taiwan	sites.	The	majority	of	the	cryptogenic	
and	HCV-	HCC	patients	were	 from	 the	United	States	whereas	 the	
majority	of	the	HBV-	HCC	patients	were	from	Taiwan.	The	US	sites	
were	more	likely	to	perform	curative	treatments	such	as	transplant	
(13.9%	vs	0.1%,	P < .001),	resection	(19.6%	vs	12.7%,	P < .001)	and	
RFA	 (11.3%	 vs	 6.4%,	 P < .001)	 (Table	 S1).	 However,	 cryptogenic	
HCC	patients	had	worse	survival	than	viral	HCC	patients	at	both	US	
and	Taiwan	sites.	At	the	US	sites,	5-	year	overall	survival	was	16.6%	
for	 the	 cryptogenic	HCC	 patients	 compared	 to	 39.8%	 and	 27.9%	
for	the	HBV-	HCC	and	HCV-	HCC	patients	respectively	(P < .001	for	
both)	 (Figure	S2A).	At	 the	Taiwan	site,	5-	year	overall	 survival	was	
15.6%	for	the	cryptogenic	HCC	patients,	27.5%	for	the	HBV-	HCC	
patients	 (P = .03)	 and	 26.2%	 for	 the	HCV-	HCC	 patients	 (P < .001)	
(Figure	S2B).
3.7 | Hepatocellular carcinoma surveillance
Data	 on	 HCC	 surveillance	 were	 available	 for	 984	 patients	 from	
Stanford	University	Medical	Center	and	the	Mayo	Clinic.	Surveillance	
was	defined	as	US	or	triphasic	CT	imaging	of	the	liver	at	6	month	in-
tervals	prior	to	the	diagnosis	of	HCC.	Surveillance	status	was	deter-
mined	through	manual	chart	review.
Of	 these,	 330	 had	 cryptogenic	 HCC,	 160	 had	 HBV-	HCC	 and	
494	 had	 HCV-	HCC.	 HCV-	HCC	 patients	 had	 a	 significantly	 higher	
rate	of	surveillance	than	cryptogenic	HCC	patients	(38.3%	vs	18.8%,	
P = .001).	 There	 was	 a	 trend	 towards	 a	 higher	 rate	 of	 surveillance	
among	 the	HBV-	HCC	patients	compared	with	 the	cryptogenic	HCC	
patients	(26.3%	vs	18.8%,	P = .058).
Among	those	under	surveillance,	there	were	no	significant	differ-
ences	in	tumour	size	or	stage	(based	on	metastases	and	Milan	criteria)	
across	aetiologies	(Table	S2).	Among	those	not	under	surveillance,	the	
cryptogenic	group	had	larger	and	more	advanced	tumours	than	either	
the	HBV	or	HCV	groups	(Table	S3).
Patients	under	surveillance	had	a	5-	year	survival	of	22.5%	com-
pared	to	17.4%	for	those	not	under	surveillance	(P <	.001)	(Figure	S3).	
HCC	 surveillance	 was	 a	 positive	 predictor	 of	 survival	 in	 univariate	
analysis	(Table	5).	However,	surveillance	was	not	included	in	the	multi-
variate	model	because	of	the	lack	of	data	from	all	sites.
4  | DISCUSSION
In	 this	 large	study	of	3878	HCC	patients,	we	 found	that	 relative	 to	
patients	 with	 HBV-	 or	 HCV-	HCC,	 patients	 with	 cryptogenic	 HCC	
were	 less	 likely	 to	have	cirrhosis,	had	 larger	 tumours,	had	more	ad-
vanced	disease,	and	had	worse	5-	year	overall	survival.	However,	HCC	
TABLE  4 Treatment	allocation,	by	hepatocellular	carcinoma	(HCC)	aetiology
Cryptogenic 
(N = 696) HBV (N = 1304) P value HCV (N = 1878) P value
Overall 
(N = 3878)
Transplant 13	(3.2%) 21	(1.7%) .062 132	(8.3%) <.001 166	(5.1%)
Resection 124	(26.6%) 204	(16.5%) <.001 180	(11.2%) <.001 508	(15.3%)
RFA 39	(9.3%) 76	(6.2%) .029 154	(9.5%) .888 269	(8.2%)
TACE 252	(54.6%) 651	(52.2%) .381 1039	(61.1%) .011 1942	(56.9%)
RE 6	(5.2%) 10	(3.5%) .449 46	(6.0%) .727 62	(5.3%)
Sorafenib 11	(2.8%) 26	(2.1%) .447 37	(2.3%) .621 74	(2.3%)
Curative	intent 174	(31.5%) 291	(23.0%) <.001 448	(26.0%) .011 913	(25.8%)
Primary treatment
Transplant 13	(2.4%) 21	(1.7%) .005 132	(7.7%) <.001 166	(4.7%)
Resection/RFA 161	(29.1%) 270	(21.4%) 316	(18.3%) 747	(21.1%)
TACE/RE 243	(43.9%) 622	(49.2%) 893	(51.7%) 1758	(49.6%)
Sorafenib 6	(1.1%) 20	(1.6%) 16	(0.9%) 42	(1.2%)
No	treatment 130	(23.5%) 331	(26.2%) 369	(21.4%) 830	(23.4%)
Curative	intent:	Transplant,	resection	or	radiofrequency	ablation.	HBV,	hepatitis	B	virus;	HCV,	hepatitis	C	virus;	RE,	radioembolization;	RFA,	radiofrequency	
ablation;	TACE,	transcatheter	arterial	chemoembolization.
P	values	are	for	the	comparison	to	cryptogenic.
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aetiology	was	not	an	 independent	predictor	of	survival	after	adjust-
ing	for	covariates	such	as	ethnicity,	cirrhosis	status,	tumour	stage	and	
treatment strategy.
It	should	be	noted	that	we	found	worse	survival	in	the	cryptogenic	
HCC	group	despite	that	group	being	more	likely	to	receive	treatments	
with	curative	intent,	particularly	surgical	resection.	It	 is	possible	that	
resection	 is	 more	 commonly	 offered	 to	 this	 group	 of	 patients	 be-
cause	cirrhosis	is	less	prevalent	compared	to	patients	with	viral	HCC.	
However,	 cryptogenic	HCC	 patients	 receiving	 resection	 or	 RFA	 still	
had	worse	survival	compared	to	viral	HCC	patients	receiving	the	same	
treatments.	The	advanced	stage	of	cryptogenic	HCC	at	presentation	is	
likely	an	important	contributor	to	this	discrepancy.	Cryptogenic	HCC	
patients	may	already	have	occult	metastases	at	presentation,	or	may	
require	 larger	 sections	of	 liver	 to	be	 resected	or	 ablated.	These	pa-
tients	also	had	more	comorbidities	which	could	reduce	overall	survival,	
such	as	CAD	and	diabetes,	though	neither	of	these	were	independent	
predictors	of	survival	in	our	model.
In	a	subset	analysis	of	patients	for	whom	we	had	HCC	surveillance	
data,	we	found	that	the	cryptogenic	group	had	lower	rates	of	surveil-
lance	than	either	of	the	viral	groups.	Those	who	had	prior	HCC	surveil-
lance	had	better	survival	than	those	who	did	not.	Among	the	patients	
under	surveillance,	there	were	no	significant	differences	in	tumour	size	
or	stage	across	the	three	aetiologies.	These	findings	suggest	that	a	lack	
of	adequate	surveillance	contributed	to	the	differences	between	the	
cryptogenic	and	viral	groups	in	tumour	stage	and	survival.
There	may	have	been	 several	barriers	 to	adequate	HCC	surveil-
lance	 in	 cryptogenic	HCC	 patients.	 Firstly,	 one-	third	 of	 cryptogenic	
HCC	patients	in	our	cohort	did	not	have	cirrhosis	and	hence	would	not	
have	met	current	criteria	for	HCC	surveillance.	Secondly,	prior	stud-
ies	 have	 reported	 lower	 HCC	 surveillance	 rates	 for	 NAFLD-	related	
cirrhosis	 compared	 to	 other	 forms	 of	 cirrhosis,	 perhaps	 because	 of	
lack	of	awareness	about	the	risk	of	NAFLD	progressing	to	HCC.14-16 
Thirdly,	 the	 sensitivity	 of	 ultrasound	 surveillance	may	 be	 limited	 in	
the	NAFLD/cryptogenic	HCC	population.	Obesity	and	NAFLD	cirrho-
sis	have	both	been	associated	with	inadequacy	of	ultrasound	for	the	
detection	of	hepatic	tumours.21,22	These	latter	two	factors	may	have	
contributed	to	our	finding	that	even	among	cirrhotic	patients,	crypto-
genic	HCC	patients	had	worse	survival.	Increasing	provider	awareness	
of	the	risk	of	HCC	in	NAFLD	may	improve	early	detection,	and	more	
work	is	needed	to	determine	whether	or	how	CT	and	MRI	screening	
should	be	 incorporated	 into	HCC	surveillance	strategies	for	patients	
with	NAFLD	or	obesity.
The	strengths	of	our	study	include	its	large	size	and	diverse	patient	
population.	To	our	knowledge,	this	is	the	largest	international	cohort	
F IGURE  1 Five-	y	overall	survival	for	patients	with	cryptogenic	and	viral	hepatocellular	carcinoma	(HCC).	A,	Overall	survival,	by	HCC	
aetiology.	B,	Overall	survival	for	cirrhotic	patients	only,	by	HCC	aetiology.	C,	Overall	survival	for	non-	cirrhotic	patients	only,	by	HCC	aetiology.	
D,	Overall	survival	for	patients	undergoing	resection	or	radiofrequency	ablation	(RFA)	as	their	primary	treatment,	by	HCC	aetiology
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that	has	been	assembled	to	compare	viral	and	non-	viral	HCC.	Our	data	
are	also	consistent	with	previous	 studies	which	 found	 that	NAFLD-	
HCC	often	arises	in	patients	without	clinically	apparent	cirrhosis	and	
that	NAFLD-	HCC	tends	 to	present	with	 larger	 tumours	and	at	 later	
stages.10-16,23-25	A	nationwide	survey	in	Japan	found	cirrhosis	in	62%	
of	 NAFLD-	HCC	 cases,	 while	 a	 US	 Department	 of	 Veterans	 Affairs	
study	found	cirrhosis	in	58.3%	of	NAFLD-	HCC	patients;	we	found	cir-
rhosis	in	66.8%	of	cryptogenic	HCC	patients	in	our	study,	consistent	
with	these	prior	reports.13,14
Ours	is	also	the	largest	study,	thus	far,	to	evaluate	survival	in	the	
cryptogenic	 HCC	 population.	 Survival	 data	 from	 prior	 studies	 have	
been	mixed,	though	the	larger	studies	generally	have	had	results	simi-
lar to ours.14,15,25,26	One	study	from	Taiwan	involving	366	cryptogenic	
HCC	patients	found	worse	long-	term	overall	survival	in	the	cryptogenic	
group	compared	to	the	viral/alcoholic	HCC	group;	this	difference	was	
no	longer	significant	after	controlling	for	confounding	variables.25 An 
Italian	study	involving	145	NAFLD-	HCC	patients	found	a	similar	pat-
tern:	worse	overall	survival	in	the	uncorrected	analysis	and	similar	sur-
vival	when	controlling	for	covariates.15	The	aforementioned	Veterans	
Affairs	study	by	Mittal	et	al	 included	120	NAFLD-	HCC	patients	and	
did	not	find	any	difference	in	1-	year	survival	compared	to	alcohol	or	
HCV-	HCC.14	Their	results	may	differ	from	ours	because	of	a	shorter	
follow-	up	period	and	factors	specific	to	the	veteran	population.
There	are	a	number	of	 limitations	to	our	study.	Firstly,	the	study	
is	retrospective	in	design,	though	our	primary	outcome	is	overall	sur-
vival,	an	objective	and	clear	outcome.	Our	cohort	is	also	drawn	from	
tertiary	 referral	 centres	and	may	not	be	 representative	of	 the	wider	
population	of	HCC	patients.	However,	our	cohort	is	geographically	di-
verse.	For	most	patients	in	our	cohort,	cirrhosis	was	diagnosed	based	
on	imaging,	laboratory	values	or	clinical	history	rather	than	liver	histol-
ogy.	These	criteria	are	not	sensitive	for	subclinical	cirrhosis	and	may	
underestimate	the	prevalence	of	cirrhosis	in	our	cohort.	We	are	also	
limited	to	discussing	cryptogenic	HCC	rather	than	NAFLD-	HCC.	We	
cannot	reliably	obtain	formal	diagnoses	of	NAFLD-	HCC	from	our	data	
despite	individual	chart	review,	as	hepatic	steatosis	is	not	reliably	pres-
ent	 in	patients	with	 advanced	 liver	 disease.	 It	 should	 also	be	noted	
that	we	did	not	evaluate	 for	occult	HBV	 infection,	which	 is	defined	
as	HBV	DNA	 in	 the	 liver	 of	 a	 patient	with	 negative	HBsAg,	Occult	
Univariate Multivariate
Predictor HR (95% CI) P value HR (95% CI) P value
Male 1.14	(1.02-	1.28) .017 0.96	(0.83-	1.11) .593
Age 1.01	(1.00-	1.01) .019 1.00	(1.00-	1.01) .492
Ethnicitya
Caucasian 1 Reference 1 Reference
Asian	(Taiwan) 0.89	(0.79-	1.00) .049 0.82	(0.68-	0.99) .039
Asian	(US) 0.59	(0.50-	0.69) <.001 0.51	(0.40-	0.64) <.001
African-	American 1.06	(0.74-	1.52) .733 0.89	(0.52-	1.51) .657
Hispanic 0.69	(0.56-	0.86) .001 0.59	(0.45-	0.77) <.001
Cirrhosis 1.55	(1.34-	1.79) <.001 1.41	(1.19-	1.68) <.001
Diabetes 1.02	(0.92-	1.14) .687
Coronary	artery	
disease	(CAD)
1.37	(1.15-	1.63) <.001 1.17	(0.87-	1.59) .300
MELD 1.05	(1.04-	1.06) <.001 1.05	(1.04-	1.06) <.001
Within	Milan	
criteria
0.30	(0.27-	0.34) <.001 0.33	(0.29-	0.38) <.001
HCC	Surveillance 0.54	(0.42-	0.70) <.001
Primary treatment
No	treatment 1 Reference 1 Reference
Curative 0.09	(0.08-	0.11) <.001 0.10	(0.08-	0.12) <.001
Palliative 0.33	(0.29-	0.36) <.001 0.35	(0.30-	0.40) <.001
Aetiology
Cryptogenic 1 Reference 1 Reference
HBV 0.69	(0.60-	0.80) <.001 0.99	(0.80-	1.22) .901
HCV 0.66	(0.58-	0.75) <.001 0.83	(0.68-	1.02) .083
HBV,	hepatitis	B	virus;	HCC,	hepatocellular	carcinoma;	HCV,	hepatitis	C	virus;	MELD,	model	for	end-	
stage liver disease.
aCaucasian,	N	=	752;	Asian	 (Taiwan),	N	=	1655;	Asian	 (US),	N	=	510;	African-	Am.,	N	=	54;	Hispanic,	
N	=	208.
TABLE  5 Predictors	of	5-	y	mortality
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HBV	infection	may	contribute	to	“cryptogenic”	HCC	in	high	prevalence	
areas	such	as	Taiwan.27
In	summary,	we	found	that	one-	third	of	cryptogenic	HCC	(most	of	
which	is	likely	related	to	NAFLD)	presented	in	patients	without	clini-
cally	apparent	cirrhosis.	Furthermore,	these	cryptogenic	HCC	patients	
were	diagnosed	at	later	stages	of	disease,	had	larger	tumours	and	had	
worse	 overall	 survival.	 The	 epidemiology	 of	 non-	viral	 non-	alcoholic	
HCC	is	different	from	that	of	viral	HCC	and	management	guidelines	
should	take	this	into	account	as	NAFLD	becomes	an	increasingly	prev-
alent	risk	factor	for	HCC.
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